Since 1987 (1), when it was discovered that human epidermal growth factor receptor 2 (HER2) amplification or overexpression in patients with breast cancer was correlated with shorter survival periods, identifying it as a key oncogenic driver, research on the HER2 gene has been relentless. The gene discussed is ERBB2; the disease is breast cancer.